Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 5.02 (Departure/Election of Directors or Officers). Martin Madaus elected director effective July 24, 2026, adding healthcare investment and operating expertise.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Martin Madaus elected director effective July 24, 2026, adding healthcare investment and operating expertise
- Expected Audit Committee and Governance and Compliance Committee appointments, strengthening oversight roles
- Shareholder election required at the 2027 annual meeting, making continued board service subject to approval
- Annual equity award approximately $200,000, aligning compensation with shareholder value
- Incentive plan expanded by 4,680,000 shares and extended through 2036, creating potential dilution but supporting long-term retention
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 92.53% quorum; all eight director nominees elected for one-year terms ending 2027
- Executive compensation received advisory approval, 39,212,253 for versus 572,620 against
- Ernst & Young LLP ratified as independent auditor for fiscal year ending April 3, 2027
- 2019 Long-Term Incentive Compensation Plan amendment approved, 37,730,923 votes for
- 2007 Employee Stock Purchase Plan amendment approved, 39,766,894 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.